Cognitive impairment has been well documented in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) mono-infections. However, in the context of HIV/HCV co-infection the research is more limited. The aim of this systematic review was to describe the characteristics of cognitive impairment in HIV/HCV co-infection and to examine the differences in cognitive performance between HIV/HCV and HIV and HCV mono-infected patients. Of the 437 records initially screened, 24 papers met the inclusion criteria and were included in the systematic review. Four studies were included in the meta-analysis. Most studies indicated that HIV/HCV co-infected patients had a higher level of cognitive impairment than HIV mono-infected patients. Meta-analysis also indicated that HIV mono-infected patients had a significantly lower global deficit score than co-infected patients. The results also indicated that co-infected patients were more likely to be impaired in information processing speed than HIV mono-infected patients. These findings can be challenged by biasing factors such as the small number of included studies, heterogeneity of the samples and a large diversity of methodological procedures. Future research with consistent and comprehensive neuropsychological batteries and covering a greater diversity of risk factors is needed, in order to clarify the effects of both viruses on cognitive function and the mechanisms that underlie these effects. Because cognitive impairments may pose significant challenges to medication adherence, quality of life and overall functioning, such knowledge may have important implications to the planning and implementation of effective interventions aimed at optimising the clinical management of these infections.
Introduction
Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) have been individually associated with cognitive impairment. Despite the era of combination antiretroviral therapy, the incidence of HIV-associated neurocognitive disorders (HAND) in milder and mild forms, defined, respectively, as asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder, has remained stable but still prevalent (Letendre, 2011; Simioni et al., 2010) . There is evidence indicating that cognitive impairment occurs in a substantial proportion (15-50%) of HIV-infected patients (Schouten, Cinque, Gisslen, Reiss, & Portegies, 2011) . Cognitive impairment has been associated with disease stage (Woods, Moore, Weber, & Grant, 2009) , poor adherence to treatment, HCV infection and other comorbid conditions such as substance use and mental illness (Anand, Springer, Copenhaver, & Altice, 2010; Cysique et al., 2009; Martin-Thormeyer & Paul, 2009 ).
Abnormalities in the neurocognitive profile of HAND have been shown in executive function, memory, information processing speed, attention/working memory, motor skills, language/verbal fluency and sensoriperception (Grant, 2008; Woods et al., 2009) . The prevalence of HIV-associated cognitive impairment is high even in patients with undetectable HIV RNA. The cause of this remains unclear, although there is evidence that immune activation, neuroinflammation, genetic and behavioural factors may have an important role (Hong & Banks, 2015; Simioni et al., 2010) .
In hepatitis C, the rates of cognitive impairment described range from 0% to 82% (Hilsabeck, Perry, & Hassanein, 2002) , and several studies demonstrated evidence of cognitive impairment across a variety of domains. Particularly, attention, concentration, working memory, executive function and psychomotor speed have been shown to be the cognitive domains most likely to be impaired (Perry, Hilsabeck, & Hassanein, 2008; Posada et al., 2009) . Several risk factors for cognitive impairment in HCV have been identified. Among these, history of alcohol and drug misuse (Foster, Goldin, & Thomas, 1998) , depression (Fontana et al., 2005) , severity of liver disease (Hilsabeck et al., 2002; Letendre et al., 2005) and high levels of pro-inflammatory cytokines (Gershon, Margulies, Gorczynski, & Heathcote, 2000) were the most consistent. Despite the complexity of mechanisms and associated risk factors, investigations of cognition in viral hepatitis have one common finding of greater disease severity being associated with more significant cognitive impairment (Córdoba et al., 2003) .
Among HIV/HCV co-infected patients, the rates of cognitive impairment are less well-defined, although it appears prevalent (Hilsabeck, Castellon, & Hinkin, 2005; Hinkin, Castellon, Levine, Barclay, & Singer, 2008; Martin-Thormeyer & Paul, 2009 ). Existing literature suggests that the presence of co-infection with both viruses leads to greater cognitive deficit than in mono-infection, though with a different pattern of cognitive impairment Martin et al., 2004) . The aim of this systematic review and meta-analysis was to bring more clarity to this area by analysing the differences on cognitive domains between HIV/HCV coinfection and HIV and HCV mono-infections, as well as to describe the characteristics of cognitive impairment in HIV/HCV co-infected patients.
Methods

Information sources and search strategy
The Cochrane Central Registered of Control Trials Library, SCOPUS, Medline, PsycINFO and ScienceDirect were systematically searched for records from the earliest data available online to April 2014. Each database was searched separately using the following key terms "cognitive impairment" AND "HIV HCV co-infection", where AND was the Boolean operator. The search was supplemented with information from references lists of the eligible articles, conferences abstracts and contact with the key academics in the field of cognitive impairment and HIV/HCV. The selection was limited to publications written in English. The study was designed according to the PRISMA statement (Moher, Liberati, Tetzlaff, & Altman, 2009 ).
Eligibility criteria
Study inclusion criteria were: (1) type of studies: prospective experimental studies concerning cognitive aspects in co-infection with HIV and HCV; retrospective cohort studies with data collected from previous medical records on cognitive domains; (2) Participants: individuals diagnosed with HIV/HCV co-infection and individuals with HIV and HCV mono-infection; (3) interventions: no intervention and all interventions, including HCV treatment. No description of intervention was necessary, as this review did not aim to compare intervention between groups; (4) primary outcome measures: any cognitive outcome measure described in the HIV/HCV co-infected group.
Data extraction
Two authors (RF and MB) independently reviewed references from electronic and non-electronic sources and selected the relevant studies. Data extraction was conducted independently (by RF and MB) and reviewed by the lead author. Disagreements were resolved by consensus. Information on the following items was extracted from each study: year of publication, design, sample size and population characteristics (e.g., gender, age, clinic stage of HIV and HCV, past and/or current intravenous drug use and domains and measures of cognitive impairment). If the full-text article did not provide sufficient data, the authors of the studies were contacted for clarification or additional data. Risk of bias assessment was undertaken on each selected study. A checklist was created based on a quality assessment instrument, and included the following items: aims explicitly stated, selection and representativeness of the sample, inclusion/ exclusion criteria, measures clearly identified, data adequately reported and discussion addressing cognitive outcomes (Higgins & Green, 2011) .
Primary outcomes
Data were extracted to address all cognitive domains available. For the meta-analysis, the global deficit score (GDS) was also extracted, which was defined as a unitary global score representing overall neuropsychological tests performances. Each individual cognitive test score was converted to T-scores demographically corrected (for education, age and gender) Rempel et al., 2013; . The meta-analyses were performed for: (a) the studies that provided a GDS score and (b) the studies that reported specific neurocognitive domains.
Data analysis
Meta-analyses quantifying the differences in cognitive impairment between co-infected and mono-infected groups were performed using the Review Manager software (RevMan; version 5.2; The Cochrane Collaboration, 2012). The meta-analysis was carried out for continuous variables using inverse variance with standardised mean differences (SMD) and 95% confidence intervals (CI). Heterogeneity was assessed using χ 2 and I 2 tests, with an I 2 more than 50% being regarded as substantial heterogeneity (Higgins & Thompson, 2002; Higgins, Thompson, Deeks, & Altman, 2003) . If significant heterogeneity was identified, a random-effects model was adopted.
Results
Study selection
The study selection process is described in Figure 1 . Briefly, the electronic search identified 434 records. Three additional records were identified by non-electronic methods of searching. After the removal of duplicates and of the initial screening (application of the pre-defined inclusion criteria and of PICO parameters), 40 full-text articles were assessed for eligibility. After full-text reading, 16 studies were further excluded and 24 studies were included in the systematic review. Four studies (16.7%) were included in the meta-analysis process.
A low risk of bias was observed when considering the identification of aims, inclusion and exclusion criteria, the procedures associated with how outcomes were determined, reporting of relevant results and discussion addressing cognitive outcomes. However, bias was found, most notably in relation to the selection of participants (e.g., a systematic difference between the characteristics of groups that were compared was identified), which limited their representativeness.
Study characteristics
The 24 studies of this systematic review included a total of 5674 participants from 6 countries (one study from Australia, Canada, Italy and Germany, three studies from the UK and 17 studies from the USA). Selected studies were published between 2004 and 2013. Study designs were largely cross-sectional (n = 14, 58.3%) and cohort (n = 8, 33.3%), and included a comparison between co-infected and HIV mono-infected groups (n = 14, 54.2%). The majority of studies included both male and female participants and two studies included only female participants (Crystal et al., 2012; Richardson et al., 2005) . The proportion of male participants ranged from 56.2% (von Giesen et al., 2004) to 100% (Martin et al., 2004; Rempel et al., 2013; Sun et al., 2013; Winston et al., 2010) . Regarding the clinical stage, 22 studies included participants in HCV chronic stage. In relation to HIV stage, the majority of studies included HIVinfected participants who were chronic and clinically stable (n = 16). General characteristics of included studies are described in Table 1 .
Cognitive impairment
Qualitative synthesis of findings Regarding cognitive impairment, the existing literature has produced inconsistent findings. Overall, most studies reported that the HIV/HCV co-infected patients were generally more impaired than HIV and HCV monoinfected patients and controls Ciccarelli et al., 2013; Clifford, Evans, Yang, & Gulick, 2005; Devlin et al., 2012; von Giesen et al., 2004; Hinkin et al., 2008; Letendre et al., 2005; Martin et al., 2004; Parsons et al., 2006; Rempel et al., 2013; Ryan, Morgello, Isaacs, Naseer, & Gerits, 2004; Sun et al., 2013; Vivithanaporn et al., 2012) . Other studies found no differences on cognitive performance between HIV/ HCV and HIV mono-infected groups (Aronow, Weston, Pezeshki, & Lazarus, 2008; Thiyagarajan et al., 2010) , between HIV/HCV and HCV mono-infected groups (Clifford et al., 2009; Perry et al., 2005) , and between HIV/HCV and both HIV and HCV mono-infected groups (Thein et al., 2007) . A qualitative synthesis of the relevant findings is presented in Table 2 .
Meta-analyses
Among the studies that measured the GDS Rempel et al., 2013; Sun et al., 2013) , the meta-analysis revealed statistically significant differences between groups (SMD = 0.56, 95% CI: 0.36, 0.75, The co-infected group showed poorer visual memory and motor functioning than the HIV mono-infected group prior to antiretroviral therapy Before cART, a greater percentage of coinfected patients performed poorly on the neuropsychology summary score (HIV/HCV: 50%; HIV: 20%). After being exposed for six months to antiretroviral therapy, no differences were found between groups HIV/HCV > HIV before cART HIV/HCV ≅ HIV after cART Perry et al. p < .00001). Specifically, the results indicated that HIV/ HCV co-infected groups were more globally impaired than HIV mono-infected groups. No significant heterogeneity among studies was detected ( Figure 2 ). Due to overlapping samples of the two studies that compared HIV/HCV co-infected and HCV mono-infected groups, the meta-analysis was not performed.
In order to explore the existence of differences between HIV/HCV co-infection and HIV and HCV mono-infections on specific cognitive domains, data from each specific domain were also combined and SMD differences with 95%CI were performed. In the meta-analysis, two studies were included (Devlin et al., 2012; Rempel et al., 2013) . The forest plots of the assessed cognitive domains are presented in Figures 3  and 4 . Regarding verbal fluency, significant heterogeneity in the meta-analysis was detected (I 2 = 61%; p = .11). Consequently, a random effects model meta-analysis was adopted. No significant difference between comparison groups was found (SMD = −0.08, 95%CI: −0.25, 0.42, p = .63). The meta-analysis of the two studies assessing information processing speed indicated that the HIV/ HCV group was more likely to report impairment in this domain than the HIV mono-infected group (SMD = −0.47, 95% CI: −0.81, −0.14, p = .006). In relation to working memory and attention, the meta-analysis revealed no differences between HIV/HCV co-infected and HIV mono-infected groups (SMD = −0.00, 95% CI: −0.34, 0.33, p = .98). No significant heterogeneity among studies was detected in these two domains.
Regarding the comparison between HIV/HCV coinfected and HCV mono-infected patients, no significant differences were found in relation to verbal fluency (SMD = −0.15, 95% CI: −0.64, 0.33, p = .53), information processing speed (SMD = −0.09, 95% CI: −0.57, 0.40, p = .72) and working memory and attention (SMD = 0.34, 95% CI: −0.15, 0.82, p = .17). No significant heterogeneity among studies was detected in these three domains.
Discussion
The aim of this systematic review was to explore the differences in cognitive impairment in co-infection with HIV and HCV, being to our knowledge the first to do so. The main contribution of this meta-analytic review is the ascertainment of the magnitude of cognitive impairment among co-infected patients, in comparison with HIV and HCV mono-infected patients. This is particularly relevant for co-infected patients, as cognitive deficits can translate into significant functional consequences, such as patients' difficulties in carrying out a range of important daily routines, which may compromise the adherence to complex treatments for HIV and hepatitis C, difficulties in remembering important information regarding the management of their disease(s), as well as reduced quality of life.
The findings of this meta-analysis indicate that HIV/ HCV co-infection is more reliably associated with GDS impairment than HIV mono-infection, reinforcing the conclusions of several individual studies (Ciccarelli et al., 2013; Hinkin et al., 2008; Letendre et al., 2005; Rempel et al., 2013) . The meta-analysis also shows that the co-infected group has significantly poorer information processing speed than the HIV mono-infected group. No differences were found between HIV/HCV co-infected and HCV mono-infected patients in the examined cognitive domains.
Our meta-analysis demonstrates that HIV/HCV patients were more impaired than HIV mono-infected patients on the GDS, which has been suggested to be a useful method to summarise results of neuropsychological assessment in HIV clinical practice (Carey et al., 2004) . This finding may reflect differences in immune biomarkers in HIV or HCV mono-infected patients compared to HIV/HCV patients (Kushner et al., 2013; Rempel et al., 2013) and suggest that the presence of HCV may have a greater impact in cognitive impairment in individuals co-infected with HIV, particularly when compared with HIV mono-infected patients. Indeed, some studies reported that HIV/HCV co-infection was an important predictor of neurocognitive impairment, attributing the difference to the adverse effect of HCV on cognition mediated by HCV viral load Sun et al., 2013) , monocyte activation , plasma inflammatory cytokine levels (Cohen et al., 2011) or the additive effects of both virus on specific brain sites . In HIV-infected patients, HCV replication in the brain has been demonstrated in the frontal cortex, white matter and basal ganglia (Letendre et al., 2007) . The acute HCV stage is characterised by an active HCV replication in the brain and has been associated with cognitive impairment in HIV/HCV . It has also been shown that HCV core protein activates human glia and potentiates HIV-associated neurotoxicity (Vivithanaporn et al., 2010) . Among HIV/HCV patients, in a study examining the white matter integrity, Stebbins et al. (2007) found a trend towards lower fractional anisotropy (FA) and a significant increase in mean diffusivity (MD) (lower FA and higher MD values typically refer to reduced neuronal integrity; Martin-Thormeyer & Paul, 2009) , therefore suggesting brain compromise among co-infected patients. However, as noted by the authors, a positive history of substance abuse was also common in the sample, which may have influenced the results. This seems to be particularly relevant to justify the lack of differences between HIV/ HCV and HCV mono-infected groups. Indeed, in the studies included in the meta-analysis, the participants of both groups had significant rates of drug abuse (>63%) and lifetime substance dependence. Thus, we cannot exclude the fact that this higher proportion of participants with history of drug misuse, which has been consistently associated with cognitive impairment (Martin-Thormeyer & Paul, 2009 ) may also have influenced our findings.
In relation to cognitive impairment in HIV, potential influencing factors may be incomplete viral suppression in the central nervous system (CNS) of HIV-infected patients, increased age, poor CNS penetration of some antiretroviral drugs, time of antiretroviral exposure, presence of drug resistance and psychiatric comorbidities (Ciccarelli et al., 2013; Nightingale et al., 2014; Rosca, Rosca, Chirileanu, & Simu, 2011; Woods et al., 2009) . It is also noteworthy that persistent cognitive impairment in HIV-infected stable patients is generally attributed to inflammatory influences. An association between inflammation, characterised by high levels of plasma cytokines and cognitive impairment has been shown in HIV/HCV (Cohen et al., 2011) . Moreover, cytokines are involved in neurodevelopmental processes (McAfoose & Baune, 2009 ). Another mechanism involved in cognitive impairment is immunosuppression; particularly, nadir CD4+ T-cells have been suggested to be an indicator of cognitive decline. For example, ANI has been associated with an increased in risk for earlier development of symptomatic HAND (Grant et al., 2014) . The authors of this study also noted that those patients with ANI had evidence of lower nadir CD4+ T-cells and were more likely to develop everyday life problems.
Overall, the diverse findings abovementioned are noteworthy and represent important advances in understanding the mechanisms underlying cognitive deficits in HIV and HCV mono-infections. However, as the CNS may be compromised by these comorbid medical conditions via additive or synergistic processes, the field of HIV/HCV co-infection and the study of joint mechanisms in cognitive impairment would still benefit from additional research.
This review also indicates that the HIV/HCV group reported more impairment in information processing speed than the HIV mono-infected group. Information processing speed describes the ability to rapidly process serial cognitive operations; when impaired, information processing speed interferes negatively with other cognitive processes due to the reduction of available information needed and the limited time for task execution (Salthouse, 1996) . Earlier studies have reported impairment in this domain as a cognitive marker of HIV-associated dementia, reflecting its broad impact on cognitive flexibility (Becker & Salthouse, 1999) . An association between HCV chronic infection and impairment in processing speed has been also reported Vigil et al., 2008) . A possible explanation for greater impairment in the coinfected patients may be the higher risk of neurotoxicity due to CNS insults by both viruses in fronto-striatal areas. Particularly, high levels of HIV have been found in the basal ganglia (notably the substantia nigra) and fronto-cortical areas (Kumar, Borodowsky, Fernandez, Gonzalez, & Kumar, 2007) , and it has been shown that fronto-striatal neuronal circuitry mediates processing speed (e.g., Fellows, Byrd, & Morgello, 2014; Kumar, Ownby, Waldrop-Valverde, Fernandez, & Kumar, 2011; Salthouse, 1996) . Additionally, there is evidence that fronto-striatal circuits are rich in dopaminergic activity and it is hypothesised that dopamine depletion exacerbates processing speed impairment in HIV (Kumar et al., 2011) .
Some limitations in this review should be acknowledged. First, the literature search was restricted to articles written in English. Second, only few studies with consistent measurement methods were identified. The lack of the consistency in the cognitive domains and measures, as well as the inability to compile a GDS from the information supplied, resulted in a rather small number of studies included in the meta-analysis. Methodological differences between the studies should also be noted, including the great heterogeneity of the samples' characteristics, the relatively small sample sizes, the predominance of studies with cross-sectional design and the large variability of cognitive measures and domains. Although the inclusion of studies of varying quality is common in most meta-analyses, these biasing factors are noteworthy and require some caution in the interpretation of the cumulative results. Studies on neurocognitive complications of HIV/HCV (as in the general HIV context) are essentially based on studies involving men, and women are still under-represented in neuropsychological studies. Moreover, it is notable that most studies were conducted in the USA (17 out of 24), and very limited research has been conducted in other settings where these diseases are more widespread.
Illicit drug use causes deficits in cognition and in combination with mental health disorders and social/behavioural factors may exacerbate cognitive impairment (Gill & Kolson, 2014; Martin-Thormeyer & Paul, 2009 ). The variability of age across studies may also affect the classification and rate of patients classified as cognitively impaired. It is possible that HIV-related cognitive impairment reported in this study may be impacted by either advanced age Sun et al., 2013) or by the emergence of cognitive decline due to AIDS indicator conditions . Another relevant factor relates to cognitive reserve (CR), which was been demonstrated to modulate cognitive impairment (Stern, 2003) , and that has been shown to be protective factor of cognitive impairment, both in HIV (Foley et al., 2012; Morgan et al., 2012 ; Vázquez-Justo, Piñón, Vergara-Moragues, Guillén-Gestoso, & Pérez-García, 2014) and HCV (Sakamoto et al., 2013) . In future research, it will be important to include appropriate controls/comparison groups, longitudinal followup of cohorts with repeated measures, comprehensive neuropsychological batteries, as well as social and behavioural factors and levels of CR that may increase the prevalence of cognitive impairment. This will be a significant opportunity to determine whether these effects are independent or additive, to identify similarities and differences in the neuropsychological patterns of HIV/ HCV co-infected and HIV and HCV mono-infected patients, as well as to clarify the discrepancies of the prevalence rates of cognitive impairment reported in the literature.
In conclusion, HIV and HCV infections have detrimental effects on neurocognitive function, which in turn may have a significant impact on patients' quality of life and overall functioning, adherence to treatments and management of risk behaviours. Patients with HIV and HCV usually present several cofactors, where interactions and cumulative effects may well increase their vulnerability to cognitive impairment. Therefore, biological, behavioural and social risk factors that could influence cognitive dysfunction need to be defined more accurately and will require special clinical attention. Moreover, with greater understanding of cognitive dysfunction, new avenues for treatment and prevention can be developed, as this knowledge may contribute to improve disease(s) management and optimise medication adherence, to facilitate treatment decision-making, to reduce risk behaviours and, ultimately, to maximise the patients' health outcomes.
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